{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:19:50Z","timestamp":1791836390782,"version":"4.3.4"},"reference-count":59,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy (TMA) that affects multiple organs and the kidneys in particular. aHUS can be sporadic or familial and is most commonly caused by dysregulation of the alternative complement pathway. The initial attack of aHUS can occur at any age, and is associated with a high rate of progression to end stage renal disease. Many aHUS patients relapse in the native or transplanted kidneys, and require close monitoring and long-term management. Availability of anticomplement therapy has revolutionized the management of aHUS, and can change the natural course of aHUS by inducing hematologic remission, improving or stabilizing kidney functions, and preventing graft failure. As a result, it is important to succeed in the challenging task of differentiating aHUS from other TMAs and initiate adequate treatment early during the course of disease. Considering the high cost of currently available anticomplement therapy, it is important also from a financial point of view to accurately diagnose aHUS early during the course of disease and determine the necessary length of therapy. This highlights the need for development of precise complement functional and genetic studies with rapid turnaround time.<\/jats:p>","DOI":"10.1182\/asheducation-2016.1.217","type":"journal-article","created":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T16:05:27Z","timestamp":1480694727000},"page":"217-225","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":74,"title":["Atypical hemolytic uremic syndrome"],"prefix":"10.1182","volume":"2016","author":[{"given":"Vahid","family":"Afshar-Kharghan","sequence":"first","affiliation":[{"name":"Section of Benign Hematology, MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"7","key":"2019111703424679300_B1","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111703424679300_B2","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMra020528","article-title":"Thrombotic microangiopathies","volume":"347","author":"Moake","year":"2002","journal-title":"N Engl J Med"},{"issue":"9464","key":"2019111703424679300_B3","first-page":"1073","article-title":"Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome","volume":"365","author":"Tarr","year":"2005","journal-title":"Lancet"},{"issue":"3","key":"2019111703424679300_B4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/jca.21276","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue","volume":"28","author":"Schwartz","year":"2013","journal-title":"J Clin Apher"},{"key":"2019111703424679300_B5","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1750-1172-6-60","article-title":"Atypical hemolytic uremic syndrome","volume":"6","author":"Loirat","year":"2011","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2019111703424679300_B6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.molimm.2015.03.246","article-title":"Atypical aHUS: state of the art","volume":"67","author":"Nester","year":"2015","journal-title":"Mol Immunol"},{"issue":"7","key":"2019111703424679300_B7","doi-asserted-by":"crossref","first-page":"834","DOI":"10.5858\/2003-127-834-TTPAHU","article-title":"Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases","volume":"127","author":"Hosler","year":"2003","journal-title":"Arch Pathol Lab Med"},{"issue":"10","key":"2019111703424679300_B8","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"2019111703424679300_B9","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"2019111703424679300_B10","doi-asserted-by":"crossref","first-page":"E1445","DOI":"10.1002\/humu.21256","article-title":"Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome","volume":"31","author":"Maga","year":"2010","journal-title":"Hum Mutat"},{"issue":"17","key":"2019111703424679300_B11","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N Engl J Med"},{"key":"2019111703424679300_B12","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1182\/asheducation.V2012.1.617.3798924","article-title":"Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated?","volume":"2012","author":"Nester","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"2019111703424679300_B13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1681\/ASN.2013050453","article-title":"Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome","volume":"25","author":"Bu","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"2019111703424679300_B14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","article-title":"An international consensus approach to the management of atypical hemolytic uremic syndrome in children","volume":"31","author":"Loirat","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"2019111703424679300_B15","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement system part I - molecular mechanisms of activation and regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol"},{"issue":"1-3","key":"2019111703424679300_B16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0162-3109(99)00015-6","article-title":"The factor H protein family","volume":"42","author":"Zipfel","year":"1999","journal-title":"Immunopharmacology"},{"issue":"2","key":"2019111703424679300_B17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0049-3848(82)90022-6","article-title":"Preparation of highly stable antithrombin-sepharose and utilization for the fractionation of heparin","volume":"26","author":"Pixley","year":"1982","journal-title":"Thromb Res"},{"issue":"1-2","key":"2019111703424679300_B18","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0162-3109(00)80300-8","article-title":"Host recognition and target differentiation by factor H, a regulator of the alternative pathway of complement","volume":"49","author":"Pangburn","year":"2000","journal-title":"Immunopharmacology"},{"key":"2019111703424679300_B19","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.molimm.2015.06.021","article-title":"Complement factor H, FHR-3 and FHR-1 variants associate in an extended haplotype conferring increased risk of atypical hemolytic uremic syndrome","volume":"67","author":"Bernab\u00e9u-Herrero","year":"2015","journal-title":"Mol Immunol"},{"issue":"4","key":"2019111703424679300_B20","doi-asserted-by":"crossref","first-page":"e60352","DOI":"10.1371\/journal.pone.0060352","article-title":"Determining the population frequency of the CFHR3\/CFHR1 deletion at 1q32","volume":"8","author":"Holmes","year":"2013","journal-title":"PLoS One"},{"key":"2019111703424679300_B21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.molimm.2015.12.005","article-title":"Heterogeneity but individual constancy of epitopes, isotypes and avidity of factor H autoantibodies in atypical hemolytic uremic syndrome","volume":"70","author":"Nozal","year":"2016","journal-title":"Mol Immunol"},{"issue":"13","key":"2019111703424679300_B22","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1182\/blood-2008-01-133702","article-title":"Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome","volume":"112","author":"Fr\u00e9meaux-Bacchi","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2019111703424679300_B23","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1073\/pnas.0603420103","article-title":"Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome","volume":"104","author":"Goicoechea de Jorge","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"2019111703424679300_B24","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa0810739","article-title":"Thrombomodulin mutations in atypical hemolytic-uremic syndrome","volume":"361","author":"Delvaeye","year":"2009","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111703424679300_B25","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/ng.2590","article-title":"Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome","volume":"45","author":"Lemaire","year":"2013","journal-title":"Nat Genet"},{"issue":"4","key":"2019111703424679300_B26","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nrneph.2014.250","article-title":"Podocyte dysfunction in atypical haemolytic uraemic syndrome","volume":"11","author":"Noris","year":"2015","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"2019111703424679300_B27","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/ajmg.10499","article-title":"Cobalamin disorder Cbl-C presenting with late-onset thrombotic microangiopathy","volume":"111","author":"Van Hove","year":"2002","journal-title":"Am J Med Genet"},{"issue":"1","key":"2019111703424679300_B28","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.ajkd.2013.08.031","article-title":"Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency","volume":"63","author":"Cornec-Le Gall","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"2019111703424679300_B29","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.hoc.2015.02.002","article-title":"Thrombotic microangiopathy: focus on atypical hemolytic uremic syndrome","volume":"29","author":"Sperati","year":"2015","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"2019111703424679300_B30","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/jth.13189","article-title":"The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies","volume":"14","author":"Phillips","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2019111703424679300_B31","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/jth.13210","article-title":"Thrombotic microangiopathy without renal involvement: two novel mutations in complement-regulator genes","volume":"14","author":"Peyvandi","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2019111703424679300_B32","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/bjh.14045","article-title":"How we manage thrombotic microangiopathies in pregnancy","volume":"173","author":"Thomas","year":"2016","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111703424679300_B33","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood-2007-04-084533","article-title":"Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome","volume":"111","author":"Fang","year":"2008","journal-title":"Blood"},{"issue":"5","key":"2019111703424679300_B34","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1681\/ASN.2009070706","article-title":"Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations","volume":"21","author":"Fakhouri","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"2019111703424679300_B35","doi-asserted-by":"crossref","first-page":"e73715","DOI":"10.1371\/journal.pone.0073715","article-title":"The interaction between factor H and Von Willebrand factor","volume":"8","author":"Feng","year":"2013","journal-title":"PLoS One"},{"issue":"11","key":"2019111703424679300_B36","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1161\/ATVBAHA.113.302280","article-title":"Human complement factor H is a reductase for large soluble von Willebrand factor multimers--brief report","volume":"33","author":"Nolasco","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"2019111703424679300_B37","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1182\/blood-2014-06-585430","article-title":"von Willebrand factor is a cofactor in complement regulation","volume":"125","author":"Feng","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2019111703424679300_B38","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.4049\/jimmunol.1301221","article-title":"Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy","volume":"191","author":"Tati","year":"2013","journal-title":"J Immunol"},{"issue":"8","key":"2019111703424679300_B39","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1182\/blood-2013-03-492421","article-title":"Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome","volume":"122","author":"Feng","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2019111703424679300_B40","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2215\/CJN.01640214","article-title":"Complement mutations in diacylglycerol kinase-\u03b5-associated atypical hemolytic uremic syndrome","volume":"9","author":"S\u00e1nchez Chinchilla","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"2019111703424679300_B41","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/bjh.12112","article-title":"Complement activation in thrombotic microangiopathies","volume":"160","author":"Feng","year":"2013","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111703424679300_B42","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1538-7836.2012.04674.x","article-title":"Complement activation in thrombotic thrombocytopenic purpura","volume":"10","author":"R\u00e9ti","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2019111703424679300_B43","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1681\/ASN.2012090884","article-title":"Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype","volume":"24","author":"Bresin","year":"2013","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"2019111703424679300_B44","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1681\/ASN.2006080811","article-title":"Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome","volume":"18","author":"Sellier-Leclerc","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2019111703424679300_B45","first-page":"1993","author":"Noris","year":"2007"},{"issue":"2","key":"2019111703424679300_B46","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.kint.2015.12.003","article-title":"Diagnosis of complement alternative pathway disorders","volume":"89","author":"Angioi","year":"2016","journal-title":"Kidney Int"},{"issue":"23","key":"2019111703424679300_B47","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1182\/blood-2015-02-629683","article-title":"Modified Ham test for atypical hemolytic uremic syndrome","volume":"125","author":"Gavriilaki","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2019111703424679300_B48","first-page":"27","article-title":"An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document","volume":"33","author":"Campistol","year":"2013","journal-title":"Nefrologia"},{"issue":"4","key":"2019111703424679300_B49","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00467-008-0964-1","article-title":"Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome","volume":"24","author":"Ariceta","year":"2009","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"2019111703424679300_B50","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1365-2141.2009.07916.x","article-title":"Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom","volume":"148","author":"Taylor","year":"2010","journal-title":"Br J Haematol"},{"issue":"11","key":"2019111703424679300_B51","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrneph.2012.214","article-title":"Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies","volume":"8","author":"Zuber","year":"2012","journal-title":"Nat Rev Nephrol"},{"issue":"9","key":"2019111703424679300_B52","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/jth.12615","article-title":"Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome","volume":"12","author":"Cugno","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"23","key":"2019111703424679300_B53","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111703424679300_B54","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int"},{"issue":"11","key":"2019111703424679300_B55","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","article-title":"Dynamics of complement activation in aHUS and how to monitor eculizumab therapy","volume":"124","author":"Noris","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2019111703424679300_B56","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.bbmt.2015.10.002","article-title":"Variable eculizumab clearance requires pharmacodynamic monitoring to optimize therapy for thrombotic microangiopathy after hematopoietic stem cell transplantation","volume":"22","author":"Jodele","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2019111703424679300_B57","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/j.ajkd.2015.04.010","article-title":"Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update","volume":"66","author":"Ardissino","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"2019111703424679300_B58","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1053\/j.ajkd.2014.01.434","article-title":"Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases","volume":"64","author":"Ardissino","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"2019111703424679300_B59","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1681\/ASN.2008080906","article-title":"Liver-kidney transplantation to cure atypical hemolytic uremic syndrome","volume":"20","author":"Saland","year":"2009","journal-title":"J Am Soc Nephrol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/217\/1251946\/hem088420.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/217\/1251946\/hem088420.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T02:23:24Z","timestamp":1657938204000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2016\/1\/217\/21126\/Atypical-hemolytic-uremic-syndrome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,2]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12,2]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2016.1.217","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,2]]}}}